DIRS.INFO The most relevant business & tech news

☆ Bayer Shares Tumble After Clinical Trial Failure, Loss in Roundup Case
▼ + stars: | 2023-11-20 | by ( Adrià Calatayud | Jared S. Hopkins | ) www.wsj.com time to read: 1 min

Bayer’s court loss on its Roundup weedkiller was the fourth decision in a row to go against the company. Photo: wolfgang rattay/ReutersBayer shares fell sharply after the company stopped a late-stage study for a blood-thinning drug early because of lack of efficacy and was told to pay $1.56 billion in a lawsuit relating to its Roundup weedkiller. Bayer said late Sunday that it discontinued a Phase 3 clinical trial to test its experimental drug asundexian for prevention of stroke and systemic embolism for patients with the heart-rhythm disorder atrial fibrillation.

Persons: wolfgang rattay, Bayer Organizations: Bayer

☆ Why Drug Companies Don’t Want to Sell Allergy Medicines and Bandages Anymore
▼ + stars: | 2023-10-27 | by ( Jared S. Hopkins | Adrià Calatayud | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/health/healthcare/sanofi-plans-to-spin-off-consumer-healthcare-business-ab808c6f

Persons: Dow Jones Organizations: sanofi

☆ Sanofi Plans to Spin Off Consumer-Healthcare, Pharma Businesses
▼ + stars: | 2023-10-27 | by ( Adrià Calatayud | ) www.wsj.com time to read: 1 min

REUTERS/Gonzalo Fuentes Photo: GONZALO FUENTES/REUTERSSanofi plans to split its consumer-healtchare and pharmaceutical operations, making it the latest big drugmaker to sharpen its focus on prescription medicines by offloading adjacent businesses. The French company outlined the plan on Friday as part of a strategic update that includes increased investment in its pipeline and a cost-savings program.

Persons: Gonzalo Fuentes, GONZALO FUENTES Organizations: Sanofi

☆ Roche to Buy Bowel-Disease Drug From Roivant, Pfizer for More Than $7 Billion
▼ + stars: | 2023-10-23 | by ( Adrià Calatayud | ) www.wsj.com time to read: 1 min

Roche’s deal is the latest example of a big pharma company turning to the deal table to bolster its pipeline of autoimmune drugs. Photo: Philipp Schmidli/Bloomberg NewsRoche Holding has agreed to buy the developer of a bowel-disease treatment from Roivant Sciences , a company started by Republican presidential candidate Vivek Ramaswamy , and Pfizer in a deal worth more than $7 billion. The Swiss pharmaceutical giant said Monday it would pay $7.1 billion upfront for Telavant Holdings, and make a near-term milestone payment of $150 million. Roche said the deal gives it rights to commercialize Telavant’s RVT-3101 drug candidate, which has shown promise for inflammatory-bowel disease and could have potential in other indications, in the U.S. and Japan.

Persons: Philipp Schmidli, Vivek Ramaswamy, Roche Organizations: pharma, Bloomberg, Roche Holding, Roivant Sciences, Republican, Pfizer, Telavant Holdings, Telavant’s Locations: Swiss, U.S, Japan

☆ Spanish Leader Calls Snap Vote After Governing Socialists Suffer Losses in Local Election
▼ + stars: | 2023-05-29 | by ( Adrià Calatayud | Ed Frankl | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/articles/spanish-leader-calls-snap-vote-after-governing-socialists-suffer-losses-in-local-election-db7d8ac8

Search resuls for: "Adrià Calatayud"

5 mentions found